Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CHRS Coherus BioSciences
8.340-0.010-0.12%
Close
01/27 16:00 ET
8.3400.0000.00%
Post Mkt Price 01/27 16:01 ET
High
8.760
Open
8.320
Turnover
7.77M
Low
8.310
Pre Close
8.350
Volume
916.79K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Coherus BioSciences (NASDAQ:CHRS) and Beam Therapeutics (NASDAQ:BEAM) Head to Head Survey
Coherus BioSciences (NASDAQ:CHRS – Get Rating) and Beam Therapeutics (NASDAQ:BEAM – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on
Coherus Biosciences Management to Meet With Truist
Coherus BioSciences (NASDAQ:CHRS) Three-year Losses Have Grown Faster Than Shareholder Returns Have Fallen, but the Stock Ascends 6.1% This Past Week
This month, we saw the Coherus BioSciences, Inc. (NASDAQ:CHRS) up an impressive 43%. But that doesn't change the fact that the returns over the last three years have been less than pleasing. After
Mizuho Securities Sticks to Their Buy Rating for Coherus Biosciences (CHRS)
Coherus Stock Dips Amid Deal to Acquire US Rights to Eylea Biosimilar FYB203
Coherus BioSciences to Buy Exclusive U.S. Commercial Rights to Eylea Biosimilar FYB203 From Klinge Biopharma >CHRS
Coherus BioSciences: Klinge to Get Total Upfront Payment of About EUR30 Million >CHRS
Coherus BioSciences: Klinge to Get Total Upfront Payment of About EUR30 Million >CHRS
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 From Klinge Biopharma
REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or Coherus BioSciences, NASDAQ:CHRS) announced today that it has executed a binding term sheet with Klinge Biopharma GmbH
Coherus BioSciences Up Nearly 18%, On Track for Largest Percent Increase Since January 2019 -- Data Talk
Coherus BioSciences, Inc. (CHRS) is currently at $10.03, up $1.52 or 17.86% --Would be highest close since Oct. 4, 2022, when it closed at $10.07 --On pace for largest percent increase since Jan. 7,
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), today announced that senior management will present at the upcoming 41st Annual J.P. Morg
Company Overview
More
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
CEO： Mr. Dennis M. Lanfear
Market： NASDAQ
Listing Date： 11/06/2014
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet